-
1
-
-
0004859527
-
Pharmacotherapy
-
Bellack AS, Hersen M, editores. New York: John Wiley and Sons
-
White K, Cole J. Pharmacotherapy. En: Bellack AS, Hersen M, editores. Handbook of comparative treatments. New York: John Wiley and Sons, 1990.
-
(1990)
Handbook of Comparative Treatments
-
-
White, K.1
Cole, J.2
-
3
-
-
0024495403
-
Efficacy of fluvoxamine in obsessive-compulsive disorder. A double blind comparision with placebo
-
Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double blind comparision with placebo. Arch Gen Psychiatry 1989;46:36-44.
-
(1989)
Arch Gen Psychiatry
, vol.46
, pp. 36-44
-
-
Goodman, W.K.1
Price, L.H.2
Rasmussen, S.A.3
Delgado, P.L.4
Heninger, G.R.5
Charney, D.S.6
-
4
-
-
33746885419
-
A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder
-
McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;59:472-3.
-
(2000)
Arch Gen Psychiatry
, vol.59
, pp. 472-473
-
-
McDougle, C.J.1
Epperson, C.N.2
Pelton, G.H.3
Wasylink, S.4
Price, L.H.5
-
5
-
-
1442284533
-
A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder
-
Denys D, van Megen HJ, van der Wee N, Westenberg HG. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry 2004;65:37-43.
-
(2004)
J Clin Psychiatry
, vol.65
, pp. 37-43
-
-
Denys, D.1
Van Megen, H.J.2
Van Der Wee, N.3
Westenberg, H.G.4
-
6
-
-
0028199065
-
Clozapine and refractory obsessive-compulsive disorder: A case report
-
Young CR, Bostic JQ, McDonald CL. Clozapine and refractory obsessive-compulsive disorder: a case report. J Clin Psychopharmacology 1994;14:209-11.
-
(1994)
J Clin Psychopharmacology
, vol.14
, pp. 209-211
-
-
Young, C.R.1
Bostic, J.Q.2
McDonald, C.L.3
-
7
-
-
0029896442
-
Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder
-
Saxena S, Wang D, Bystritsky A, Baxter LR Jr. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996;57:303-6.
-
(1996)
J Clin Psychiatry
, vol.57
, pp. 303-306
-
-
Saxena, S.1
Wang, D.2
Bystritsky, A.3
Baxter Jr., L.R.4
-
8
-
-
0034034191
-
Beneficial effect of olanzapine in schizophrenic patients with obsessive-sompulsive symptoms
-
Poyurovsky M, Dorfman-Etrog P, Haggai-Hermes H, Munitz H, Tollefson GD, Weizman A. Beneficial effect of olanzapine in schizophrenic patients with obsessive-sompulsive symptoms. Internat Clin Psychopharmacol 2000;15:169-73.
-
(2000)
Internat Clin Psychopharmacol
, vol.15
, pp. 169-173
-
-
Poyurovsky, M.1
Dorfman-Etrog, P.2
Haggai-Hermes, H.3
Munitz, H.4
Tollefson, G.D.5
Weizman, A.6
-
9
-
-
0036677162
-
Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: An open-label study
-
Denys D, Van Megen H, Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study. J Clin Psychiatry 2002;63:700-3.
-
(2002)
J Clin Psychiatry
, vol.63
, pp. 700-703
-
-
Denys, D.1
Van Megen, H.2
Westenberg, H.3
-
10
-
-
0030711107
-
Udate on pharmacologic management of OCD: Agents and augmentation
-
McDougle CJ. Udate on pharmacologic management of OCD: Agents and augmentation. J Clin Psychiatry 1997;58:11-7.
-
(1997)
J Clin Psychiatry
, vol.58
, pp. 11-17
-
-
McDougle, C.J.1
-
11
-
-
0035902983
-
Ziprasidone: A novel antipsychotic agent with a unique human receptor binding profile
-
Schmidt AW, Lebel LA, Howard HR. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 2001;425:197-201.
-
(2001)
Eur J Pharmacol
, vol.425
, pp. 197-201
-
-
Schmidt, A.W.1
Lebel, L.A.2
Howard, H.R.3
-
12
-
-
0036314871
-
Stimulation of 5-hydroxytryptamine (5-HT2C) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex
-
Pozzy L, Acconcia S, Ceglia I, Invernizzi RW, Samanin R. Stimulation of 5-hydroxytryptamine (5-HT2C) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex. J Neurochem 2002;82:93-100.
-
(2002)
J Neurochem
, vol.82
, pp. 93-100
-
-
Pozzy, L.1
Acconcia, S.2
Ceglia, I.3
Invernizzi, R.W.4
Samanin, R.5
-
13
-
-
0036711059
-
SR46349-B, a 5-HT (2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens
-
Bonaccorso S, Meltzer HY, Li Z, Day J, Alboszta AR, Ichikawa J. SR46349-B, a 5-HT (2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology 2002;27:430-41.
-
(2002)
Neuropsychopharmacology
, vol.27
, pp. 430-441
-
-
Bonaccorso, S.1
Meltzer, H.Y.2
Li, Z.3
Day, J.4
Alboszta, A.R.5
Ichikawa, J.6
-
14
-
-
0036848458
-
Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder
-
Bymaster FP, Katner JS, Nelson DL, Hemrik-Luecke SK, Threlkeld PG, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002;27:699-711.
-
(2002)
Neuropsychopharmacology
, vol.27
, pp. 699-711
-
-
Bymaster, F.P.1
Katner, J.S.2
Nelson, D.L.3
Hemrik-Luecke, S.K.4
Threlkeld, P.G.5
-
15
-
-
0033696731
-
Improving the treatment of schizophrenia: Focus on serotonin (5-HT1A) receptors
-
Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT1A) receptors. J Pharmacol Exp Ther 2000;295: 853-61.
-
(2000)
J Pharmacol Exp Ther
, vol.295
, pp. 853-861
-
-
Millan, M.J.1
-
16
-
-
0027439207
-
Neurobiological mechanism involved in anti-depressant therapies
-
Briley M, Moret C. Neurobiological mechanism involved in anti-depressant therapies. Clin Neuropharmcol 1993;16:387-400.
-
(1993)
Clin Neuropharmcol
, vol.16
, pp. 387-400
-
-
Briley, M.1
Moret, C.2
-
17
-
-
0028875303
-
Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor activity
-
Seeger TF, Seymour PA, Schmidt AW, Schmidt AW, Zorn SH, Schulz DW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor activity. J Pharmacol Exp Ther 1995;275:101-13.
-
(1995)
J Pharmacol Exp Ther
, vol.275
, pp. 101-113
-
-
Seeger, T.F.1
Seymour, P.A.2
Schmidt, A.W.3
Schmidt, A.W.4
Zorn, S.H.5
Schulz, D.W.6
|